Edmond, EC

Menke, R

Proudfoot, M

Stagg, CJ

Talbot, K

Turner, MR

Edmond, Evan

Menke, Ricarda

Proudfoot, Malcolm

Talbot, Kevin

Stagg, Charlotte

Turner, Martin R

Oxford University Research Archive

Therapeutic options for the fatal neurodegenerative disorder ALS are urgently needed. Trials rely on blunt outcome measures such as survival because of a lack of objective markers of disease activity and progression. The C9orf72 hexanucleotide repeat expansion (HRE) is associated with 10% of all cases of ALS, bringing the near-future prospect of oligonucleotide therapeutic trials. The development of biomarkers will reduce trial duration and cost by providing more sensitive measures of disease-slowing and/or evidence of target engagement. ALS is consistently associated with cortical hyperexcitability (CE), based on transcranial magnetic paired stimulation (TMS) to induce short-interval cortical inhibition (SICI). This project builds on the potential shown by non-invasive neuroimaging to provide biomarkers in ALS. We develop functional neuroimaging biomarkers that reflect the phenomenon of CE, including markers of pre-symptomatic pathology. Affected ALS patients carrying the C9orf72 HRE and a group of asymptomatic carriers are studied using a combined functional MRI (FMRI and MRS) and neurophysiological (MEG) readout. This study offers novel non-invasive biomarkers based on a consistent neurophysiological mechanism in ALS to advance therapeutic development.  

English

Motor system biomarkers in amyotrophic lateral sclerosis

Motor system biomarkers in amyotrophic lateral sclerosis

Abstract

Similar works

Full text

Available Versions

Oxford University Research Archive